2025 Q4 -tulosraportti
59 päivää sitten
‧48 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 627 | - | - | ||
| 33 | - | - | ||
| 221 | - | - | ||
| 68 | - | - | ||
| 217 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·18 t sittenHopefully the company won't be acquired now, from these levels it can become a real stock market rocket - if it gets to develop for a year or so!
·19 t sittenReally waiting for DNB's analyst to soon say something about Cevira. https://asieris.com/asieris-pharmaceuticals-releases-2025-annual-report%EF%BC%9Aflagship-product-approval-marks-inflection-point-commercialization-2-0-drives-growth/·18 t sittenThis is from quartr ai, so take it with a grain of salt Asieris 2025 annual report — implications for Photocure The news from Photocure's partner Asieris Pharmaceuticals is directly relevant to Photocure on two fronts: CEVIRA® (APL-1702) and Hexvix®. CEVIRA® — a major milestone trigger for Photocure In July 2019, Photocure entered into a license agreement granting Asieris a worldwide license to develop and commercialize CEVIRA®. The March 2026 approval of CEVIRA® by China's NMPA is highly significant for Photocure financially: Photocure has already received USD 17.0 million in milestone payments to date (including a USD 5.0 million signing fee in 2019 and subsequent development milestones). The China regulatory approval triggers a USD 11.0 million milestone payment to Photocure. Additional milestones of up to USD 31.0 million are eligible for regulatory submissions and approvals of CEVIRA® in Europe and the U.S. A second indication could trigger up to USD 16.0 million in additional milestone payments. Photocure is eligible for royalties of 10–20% on global sales, plus cumulative sales-based milestones of up to USD 190.0 million (with a significant portion triggered if the product achieves blockbuster status). Asieris' disclosure that it has submitted a Marketing Authorization Application to the European Medicines Agency and is in dialogue with the U.S. FDA on a Phase III trial design opens the path to further European and U.S. milestones for Photocure. Hexvix® — commercial launch now in sight Hexvix® (China's first approved blue-light imaging agent for bladder cancer) has its marketing authorization in China. The key missing piece had been device approval for the Richard Wolf SYSTEM BLUE blue-light cystoscopy system — which, per Asieris' report, received market approval in April 2026. This was flagged as imminent in Photocure's Q4 2025 earnings call. Photocure is eligible for manufacturing, milestone, and royalty payments based on future Hexvix® sales in China. Context from Photocure's Q4 2025 results As of Q4 2025, Photocure had received over USD 18 million in total milestones across both the Hexvix® and CEVIRA® programs. Photocure received no milestone revenues in 2025 (milestones of ~NOK 33.7 million were received in 2024). The USD 11.0 million China approval milestone for CEVIRA® would therefore represent a meaningful revenue event for Photocure in 2026, given Photocure's full-year 2025 total revenues were NOK 532.6 million (~USD 50 million).
·19 t sitten · MuokattuTime for a solid repricing now
·18 t sitten · MuokattuDo you have any idea how much money is potentially involved annually?·18 t sittenNo matter how much it is, it goes straight to the bottom line for pho.- ·19 t sittenWhere do you see that, stock exchange announcement?, and what does that and several positive news recently mean for growth and revenues for photocure in the coming years.·19 t sittenAsieris' annual report. Approved now in April, but not reported to the stock exchange since the shoe manufacturer is not on the stock exchange.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
59 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·18 t sittenHopefully the company won't be acquired now, from these levels it can become a real stock market rocket - if it gets to develop for a year or so!
- ·19 t sittenReally waiting for DNB's analyst to soon say something about Cevira. https://asieris.com/asieris-pharmaceuticals-releases-2025-annual-report%EF%BC%9Aflagship-product-approval-marks-inflection-point-commercialization-2-0-drives-growth/·18 t sittenThis is from quartr ai, so take it with a grain of salt Asieris 2025 annual report — implications for Photocure The news from Photocure's partner Asieris Pharmaceuticals is directly relevant to Photocure on two fronts: CEVIRA® (APL-1702) and Hexvix®. CEVIRA® — a major milestone trigger for Photocure In July 2019, Photocure entered into a license agreement granting Asieris a worldwide license to develop and commercialize CEVIRA®. The March 2026 approval of CEVIRA® by China's NMPA is highly significant for Photocure financially: Photocure has already received USD 17.0 million in milestone payments to date (including a USD 5.0 million signing fee in 2019 and subsequent development milestones). The China regulatory approval triggers a USD 11.0 million milestone payment to Photocure. Additional milestones of up to USD 31.0 million are eligible for regulatory submissions and approvals of CEVIRA® in Europe and the U.S. A second indication could trigger up to USD 16.0 million in additional milestone payments. Photocure is eligible for royalties of 10–20% on global sales, plus cumulative sales-based milestones of up to USD 190.0 million (with a significant portion triggered if the product achieves blockbuster status). Asieris' disclosure that it has submitted a Marketing Authorization Application to the European Medicines Agency and is in dialogue with the U.S. FDA on a Phase III trial design opens the path to further European and U.S. milestones for Photocure. Hexvix® — commercial launch now in sight Hexvix® (China's first approved blue-light imaging agent for bladder cancer) has its marketing authorization in China. The key missing piece had been device approval for the Richard Wolf SYSTEM BLUE blue-light cystoscopy system — which, per Asieris' report, received market approval in April 2026. This was flagged as imminent in Photocure's Q4 2025 earnings call. Photocure is eligible for manufacturing, milestone, and royalty payments based on future Hexvix® sales in China. Context from Photocure's Q4 2025 results As of Q4 2025, Photocure had received over USD 18 million in total milestones across both the Hexvix® and CEVIRA® programs. Photocure received no milestone revenues in 2025 (milestones of ~NOK 33.7 million were received in 2024). The USD 11.0 million China approval milestone for CEVIRA® would therefore represent a meaningful revenue event for Photocure in 2026, given Photocure's full-year 2025 total revenues were NOK 532.6 million (~USD 50 million).
- ·19 t sitten · MuokattuTime for a solid repricing now·18 t sitten · MuokattuDo you have any idea how much money is potentially involved annually?·18 t sittenNo matter how much it is, it goes straight to the bottom line for pho.
- ·19 t sittenWhere do you see that, stock exchange announcement?, and what does that and several positive news recently mean for growth and revenues for photocure in the coming years.·19 t sittenAsieris' annual report. Approved now in April, but not reported to the stock exchange since the shoe manufacturer is not on the stock exchange.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 627 | - | - | ||
| 33 | - | - | ||
| 221 | - | - | ||
| 68 | - | - | ||
| 217 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
2025 Q4 -tulosraportti
59 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·18 t sittenHopefully the company won't be acquired now, from these levels it can become a real stock market rocket - if it gets to develop for a year or so!
- ·19 t sittenReally waiting for DNB's analyst to soon say something about Cevira. https://asieris.com/asieris-pharmaceuticals-releases-2025-annual-report%EF%BC%9Aflagship-product-approval-marks-inflection-point-commercialization-2-0-drives-growth/·18 t sittenThis is from quartr ai, so take it with a grain of salt Asieris 2025 annual report — implications for Photocure The news from Photocure's partner Asieris Pharmaceuticals is directly relevant to Photocure on two fronts: CEVIRA® (APL-1702) and Hexvix®. CEVIRA® — a major milestone trigger for Photocure In July 2019, Photocure entered into a license agreement granting Asieris a worldwide license to develop and commercialize CEVIRA®. The March 2026 approval of CEVIRA® by China's NMPA is highly significant for Photocure financially: Photocure has already received USD 17.0 million in milestone payments to date (including a USD 5.0 million signing fee in 2019 and subsequent development milestones). The China regulatory approval triggers a USD 11.0 million milestone payment to Photocure. Additional milestones of up to USD 31.0 million are eligible for regulatory submissions and approvals of CEVIRA® in Europe and the U.S. A second indication could trigger up to USD 16.0 million in additional milestone payments. Photocure is eligible for royalties of 10–20% on global sales, plus cumulative sales-based milestones of up to USD 190.0 million (with a significant portion triggered if the product achieves blockbuster status). Asieris' disclosure that it has submitted a Marketing Authorization Application to the European Medicines Agency and is in dialogue with the U.S. FDA on a Phase III trial design opens the path to further European and U.S. milestones for Photocure. Hexvix® — commercial launch now in sight Hexvix® (China's first approved blue-light imaging agent for bladder cancer) has its marketing authorization in China. The key missing piece had been device approval for the Richard Wolf SYSTEM BLUE blue-light cystoscopy system — which, per Asieris' report, received market approval in April 2026. This was flagged as imminent in Photocure's Q4 2025 earnings call. Photocure is eligible for manufacturing, milestone, and royalty payments based on future Hexvix® sales in China. Context from Photocure's Q4 2025 results As of Q4 2025, Photocure had received over USD 18 million in total milestones across both the Hexvix® and CEVIRA® programs. Photocure received no milestone revenues in 2025 (milestones of ~NOK 33.7 million were received in 2024). The USD 11.0 million China approval milestone for CEVIRA® would therefore represent a meaningful revenue event for Photocure in 2026, given Photocure's full-year 2025 total revenues were NOK 532.6 million (~USD 50 million).
- ·19 t sitten · MuokattuTime for a solid repricing now·18 t sitten · MuokattuDo you have any idea how much money is potentially involved annually?·18 t sittenNo matter how much it is, it goes straight to the bottom line for pho.
- ·19 t sittenWhere do you see that, stock exchange announcement?, and what does that and several positive news recently mean for growth and revenues for photocure in the coming years.·19 t sittenAsieris' annual report. Approved now in April, but not reported to the stock exchange since the shoe manufacturer is not on the stock exchange.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 627 | - | - | ||
| 33 | - | - | ||
| 221 | - | - | ||
| 68 | - | - | ||
| 217 | - | - |
Välittäjätilasto
Dataa ei löytynyt